We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Polysome Screen Identifies Cancer Related MicroRNAs

By LabMedica International staff writers
Posted on 04 Sep 2018
Print article
Image: A micrograph of a pleural fluid cytopathology specimen showing mesothelioma (Photo courtesy of Wikimedia Commons).
Image: A micrograph of a pleural fluid cytopathology specimen showing mesothelioma (Photo courtesy of Wikimedia Commons).
An international research team has developed a polysome-based method for detecting microRNAs (miRNAs) that act to promote or sustain growth of malignant mesothelioma and other types of cancer.

MicroRNAs are short RNA molecules about 22 nucleotides in length. Essentially, miRNAs specifically target certain messenger RNAs (mRNAs) to prevent them from coding for a specific protein. The expression of miRNAs in cancer has been widely studied and has allowed this activity to be classified as oncomir (also oncomiR) or oncosuppressor.

The dysregulation of oncomirs has been associated with specific cancer forming events such as malignant transformation and metastasis. Some oncomir genes are oncogenes, in that overexpression of the gene leads to cancerous growth. Other oncomir genes are tumor suppressors in a normal cell, so that under expression of the gene leads to cancerous growth.

In order to identify biologically active oncomirs, investigators at the National Institute of Molecular Genetics (Milan, Italy) and their collaborators in Italy and the United States developed a screen for miRNAs acting on the polysomes of malignant mesothelioma (MPM) cells. A polysome (or polyribosome) is a complex comprising an mRNA molecule and two or more ribosomes that act to translate mRNA instructions into polypeptides.

They investigators reported in the August 2, 2018, online edition of the journal Cancer Research that only a small percentage of expressed miRNAs physically associated with polysomes. On polysomes, they identified miRNAs already characterized in MPM, as well as novel ones like miR-24-3p, which acted as a pro-migratory miRNA in all cancer cells tested. They found that miR-24-3p positively regulated the activity of the enzyme Rho-GTP, a kinase involved in regulating the shape and movement of cells by acting on the cytoskeleton. In contrast, inhibition of miR-24-3p reduced growth in MPM cells.

Among the specific targets of miR-24-3p was cingulin, a tight junction protein that inhibited Rho-GTP activity. Overexpression of miR-24-3p was found to only partially inhibit cingulin mRNA but to completely eliminate cingulin protein, confirming its action via translational repression. This finding confirmed that miR-24-3p was an oncomir, and suggested that identification of polysome-associated miRNAs efficiently sorted out biologically active miRNAs from inactive ones.

“We have identified a novel approach for identifying relevant miRNA in cancer biology,” said senior author Dr. Stefano Biffo, professor of cell biology at the University of Milan (Italy) and group leader at the National Institute of Molecular Genetics. “By examining the polyribosomes where translation occurs, this "focused" search has allowed us to identify that miR-24-3p (a particular miRna) expression is relevant to cancer progression and metastasis.”

Related Links:
National Institute of Molecular Genetics
University of Milan

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.